Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. UVA-F-0794
Published by: Darden Business Publishing
Originally published in: 1988
Version: Rev 9.90
Length: 17 pages
Data source: Field research

Abstract

This negotiation case is meant to be used in conjunction with 'Hybritech, Incorporated (A)'; half the class works from one case and half from the other. Lilly is considering acquiring Hybritech, but the genetic-engineering company's future cash flows are difficult to predict and value. Both companies want to effect the merger, but the cases, which provide essentially the same information in all other respects, provide widely divergent projected cash flows. The 'Hybritech, Incorporated (B)' is the follow-up case dealing with the payment structure of the acquisition.

About

Abstract

This negotiation case is meant to be used in conjunction with 'Hybritech, Incorporated (A)'; half the class works from one case and half from the other. Lilly is considering acquiring Hybritech, but the genetic-engineering company's future cash flows are difficult to predict and value. Both companies want to effect the merger, but the cases, which provide essentially the same information in all other respects, provide widely divergent projected cash flows. The 'Hybritech, Incorporated (B)' is the follow-up case dealing with the payment structure of the acquisition.

Settings


Related